Metastatic Malignant Neoplasm to the Leptomeninges Not Yet Recruiting Phase Trials for Almonertinib (DB16640)

Also known as: Leptomeningeal Metastasis / Neoplastic Meningitis / Leptomeningeal Metastases / Metastatic Malignant Neoplasm in the Leptomeninges / Leptomeningeal Disease (LMD) / Leptomeningeal Disease / Lymphomatous meningitis / Leptomeningeal Carcinomatosis / Metastatic malignant neoplasm to leptomeninges (disorder) / Lymphomatous meningitis (disorder) / Malignant meningitis (disorder) / Leptomeningeal Neoplasms / Meningeal dissemination / Metastases to meninges / Meningeal Carcinomatosis

IndicationStatusPhase
DBCOND0057483 (Metastatic Malignant Neoplasm to the Leptomeninges)Not Yet RecruitingNot Available
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04944069Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal MetastasisTreatment